下调和上调
翻译(生物学)
细胞生物学
癌症免疫疗法
癌症研究
免疫疗法
T细胞
化学
生物
细胞
甲基转移酶
HEK 293细胞
信使核糖核酸
阻塞(统计)
苏拉明
STAT1
磷酸化
翻译效率
细胞培养
核糖核酸
综合应力响应
细胞分化
细胞生长
转录组
免疫
免疫系统
癌细胞
分子生物学
作者
Jiansong Huang,Jing Zhou,Xiao Liu,Xiaoxu Liu,Ye Xiao,Kai Li,Chenbo Ding,Xuemin Cai,Wenli Mao,Changfen Xu,Yuxin Kong,Yu Deng,Xiaohan Song,Mei Yang,Daohai Du,Siqi Guo,Kaixian Chen,Cheng Luo,Chengqi Yi,Shijie Chen
标识
DOI:10.1038/s41467-026-75269-1
摘要
Naïve T cells maintain a delicate balance between quiescence and rapid activation, which involves multiple layers of regulation beyond transcription. Here, we identify the RNA modification N6,2’-O-dimethyladenosine (m6Am) and its methyltransferase PCIF1 as critical enforcers of T cell quiescence. During CD4+ T cell activation, m6Am levels are dynamically downregulated. T-cell-specific PCIF1 knockout (cKO) mice exhibit potent tumor suppression, driven by enhanced Th1 differentiation and subsequent amplification of NK cell cytotoxicity. Mechanistically, PCIF1 represses STAT1 translation via m6Am modification of its mRNA, thereby constraining Th1 commitment. Activation-induced PCIF1 downregulation releases this translational brake, enabling rapid Th1 polarization. Crucially, we identify Suramin as a pharmacological PCIF1 inhibitor that disrupts m6Am modification, boosts Th1 responses, and suppresses tumor growth. Our findings establish the PCIF1-m6Am-STAT1 axis as a translational checkpoint governing T cell differentiation and suggest that targeting PCIF1 represents a potential strategy for tumor immunotherapy. Phosphorylated CTD interaction factor 1(PCIF1) is the sole enzyme catalyzing the post-transcriptional N6-methyladenosine(m6A) modification for mRNA. Here the authors show, by genomic deletion of PCIF1specifically in T cells, that PCIF1 represses STAT1 translation via this important mRNA modification, and thereby preventing T cell activation and enforcing a naïve T cell phenotype.
科研通智能强力驱动
Strongly Powered by AbleSci AI